PapersFlow Research Brief
Intraperitoneal and Appendiceal Malignancies
Research Guide
What is Intraperitoneal and Appendiceal Malignancies?
Intraperitoneal and appendiceal malignancies refer to cancers involving the peritoneal cavity, such as peritoneal carcinomatosis from colorectal, gastric, and ovarian origins, along with appendiceal neoplasms like pseudomyxoma peritonei, managed primarily through cytoreductive surgery and intraperitoneal chemotherapy.
This field encompasses 31,057 papers on the management of peritoneal carcinomatosis from digestive tract cancers, including colorectal and gastric cancer, with studies on cytoreductive surgery, intraperitoneal chemotherapy, and hyperthermic intraperitoneal chemotherapy. Key topics include survival analysis in patients with peritoneal metastases, pseudomyxoma peritonei, and appendiceal neoplasms. Research also addresses peritoneal surface malignancy treatment.
Topic Hierarchy
Research Sub-Topics
Cytoreductive Surgery
Research evaluates peritonectomy techniques and visceral resections to achieve complete cytoreduction (CC-0/1). Studies correlate surgical completeness scores with long-term survival outcomes.
Hyperthermic Intraperitoneal Chemotherapy
This sub-topic investigates HIPEC protocols, drug penetration, and hyperthermia synergies during cytoreduction. Researchers conduct randomized trials comparing HIPEC to systemic therapy alone.
Peritoneal Carcinomatosis from Colorectal Cancer
Studies analyze PCI staging, treatment selection, and survival patterns specific to colorectal PM. Research develops risk stratification models incorporating synchronous versus metachronous disease.
Pseudomyxoma Peritonei
Research covers molecular pathogenesis, mucin production, and optimal CRS/HIPEC strategies for low/high-grade PMP. Long-term studies track recurrence patterns and functional outcomes.
Appendiceal Neoplasms
This area classifies goblet cell carcinoids, LAMN, and HAMN with peritoneal dissemination patterns. Researchers study biomarker correlations and tailored treatment algorithms.
Why It Matters
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves median survival to 22.3 months compared to 12.6 months with systemic chemotherapy alone in patients with peritoneal carcinomatosis from colorectal cancer, as shown in a randomized trial by Verwaal et al. (2003). Maximal cytoreductive surgery enhances survival in advanced ovarian carcinoma, with each 10% increase in cytoreduction linked to a 5.5% decrease in mortality risk during the platinum era, per Bristow et al. (2002) meta-analysis of 81 cohorts. Peritonectomy procedures enable complete removal of peritoneal surface malignancy, supporting early postoperative intraperitoneal chemotherapy for long-term disease-free survival, according to Sugarbaker (1995). These approaches address peritoneal metastases, a common progression site in gastrointestinal and ovarian cancers.
Reading Guide
Where to Start
"Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer" by Verwaal et al. (2003), as it provides a foundational randomized trial directly comparing treatments central to intraperitoneal malignancies with clear survival data.
Key Papers Explained
Verwaal et al. (2003) established HIPEC superiority over systemic chemotherapy for colorectal peritoneal carcinomatosis, building on Sugarbaker (1995) peritonectomy techniques that enable such cytoreduction. Bristow et al. (2002) meta-analysis quantifies cytoreduction's survival impact in ovarian cases, complementing Jacquet and Sugarbaker (1996) staging methodologies for patient selection. Armstrong et al. (2006) demonstrates intraperitoneal chemotherapy benefits, extending principles from Verwaal to ovarian contexts.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Frontiers emphasize refining cytoreductive surgery outcomes in appendiceal neoplasms and pseudomyxoma peritonei, with ongoing needs for standardized staging per Jacquet and Sugarbaker (1996) and peritonectomy optimization from Sugarbaker (1995). No recent preprints or news available.
Papers at a Glance
Frequently Asked Questions
What is the survival benefit of intraperitoneal chemotherapy in ovarian cancer?
Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival compared to intravenous paclitaxel plus cisplatin in optimally debulked stage III ovarian cancer, as demonstrated by Armstrong et al. (2006). This Gynecologic Oncology Group study showed superior outcomes with the intraperitoneal regimen.
How does cytoreductive surgery affect survival in advanced ovarian cancer?
Maximal cytoreductive surgery reduces mortality risk, with each 10% increase in maximal cytoreduction associated with a 5.5% decrease in risk among stage III/IV patients treated with platinum-based chemotherapy, per Bristow et al. (2002) meta-analysis. Optimal debulking correlates with improved prognosis across cohorts.
What is the role of HIPEC in peritoneal carcinomatosis from colorectal cancer?
Cytoreduction with HIPEC yields a median survival of 22.3 months versus 12.6 months with systemic chemotherapy and palliative surgery in peritoneal carcinomatosis of colorectal origin, according to Verwaal et al. (2003) randomized trial. The approach confirms superiority over standard treatment.
What are peritonectomy procedures used for?
Peritonectomy procedures prepare the abdomen for cytoreductive surgery and early postoperative intraperitoneal chemotherapy in peritoneal carcinomatosis, peritoneal sarcomatosis, or mesothelioma, as described by Sugarbaker (1995). They facilitate complete tumor removal from peritoneal surfaces.
How do neoadjuvant chemotherapy and primary surgery compare in advanced ovarian cancer?
Neoadjuvant chemotherapy followed by interval debulking surgery is not inferior to primary debulking surgery followed by chemotherapy in stage IIIC/IV ovarian cancer, with complete resection of macroscopic disease achievable in both, per Vergote et al. (2010). This supports neoadjuvant as a viable option for bulky disease.
What methodologies assess peritoneal carcinomatosis?
Clinical research methodologies for diagnosis and staging of peritoneal carcinomatosis include standardized approaches to evaluate extent and resectability, as outlined by Jacquet and Sugarbaker (1996). These aid in selecting patients for cytoreductive therapy.
Open Research Questions
- ? What factors determine optimal patient selection for cytoreduction and HIPEC in appendiceal neoplasms beyond colorectal carcinomatosis?
- ? How does the extent of peritoneal metastases influence long-term survival post-peritonectomy in pseudomyxoma peritonei?
- ? Which intraperitoneal chemotherapy regimens maximize efficacy while minimizing toxicity in gastric cancer peritoneal metastases?
- ? What biomarkers predict response to maximal cytoreductive surgery in appendiceal malignancies?
- ? How can staging methodologies for peritoneal surface malignancies be standardized across institutions?
Recent Trends
The field maintains 31,057 works with no specified 5-year growth rate; top-cited papers from 1990-2014 continue to define standards, such as Verwaal et al. on HIPEC for colorectal carcinomatosis and Bristow et al. (2002) on cytoreduction meta-analysis.
2003No recent preprints or news reported in the last 6-12 months.
Research Intraperitoneal and Appendiceal Malignancies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Intraperitoneal and Appendiceal Malignancies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers